Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269925 | 1.00 | TDP1 (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL9614447 | 0.99 | KDM4E (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL6858825 | 0.95 | NPY4R (0.46) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL29543910 | 0.93 | CA12 (0.47) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL7208685 | 0.93 | CA12 (0.47) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL7208677 | 0.93 | CA12 (0.47) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL18190281 | 0.92 | TDP1 (0.46) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL7204729 | 0.92 | KDM4E (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL8499114 | 0.92 | KDM4E (0.48) | TDP1CA12CA1CA9KDM4E | |
| SCHEMBL7204719 | 0.92 | KDM4E (0.48) | TDP1CA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731250-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN FOR USE IN TREATING NON-VIRAL INFLAMMATORY DISEASES OF THE LUNG | AATEC Medical GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731249-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN | AATEC Medical GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4730999-A1 | RECOMBINANT AAT FROM YEAST TO TREAT TRANSPLANTS | AATEC Medical GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731251-A1 | RECOMBINANT AAT FROM YEAST TO TREAT BACTERIAL RESPIRATORY INFECTIONS | AATEC Medical GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-12421298-B2 | Compositions and methods for evaluating anticoagulant therapeutic efficacy | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024261175-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN FOR USE IN TREATING NON-VIRAL INFLAMMATORY DISEASES OF THE LUNG | AATEC MEDICAL GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261171-A1 | RECOMBINANT AAT FROM YEAST TO TREAT TRANSPLANTS | AATEC MEDICAL GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261142-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN | AATEC MEDICAL GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261179-A1 | RECOMBINANT AAT FROM YEAST TO TREAT BACTERIAL RESPIRATORY INFECTIONS | AATEC MEDICAL GMBH (DE) | 2024-12-26 | — | — | WO | disclosed |
| EP-4453233-A1 | ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | AATEC Medical GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240132457-A1 | 3-(2-(BENZO[D]THIAZOL-2-YL)-2-(PHENYLSUFONAMIDO)ETHYL)BENZIMIDAMIDE DERIVATIVES AND RELATED COMPOUNDS AS TMPRSS2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS | INTEGERBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4299585-A2 | COMPOSITIONS AND METHODS FOR ANTI-THROMBOTIC AND HEMOSTATIC THERAPIES | The Scripps Research Institute (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3455636-B1 | COMPOSITIONS AND METHODS FOR ANTI-THROMBOTIC AND HEMOSTATIC THERAPIES | SCRIPPS RESEARCH INST (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023118424-A1 | ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | AATEC MEDICAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-116322660-A | Micronutrient combinations to inhibit coronavirus cell infection | 马提亚斯·W·拉斯 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023001634-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COVID-19 COMPRISING OTAMIXABAN AND AT LEAST ONE OF CAMOSTAT AND NAFAMOSTAT | FREIE UNIVERSITÄT BERLIN (DE) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132457-A1 | 3-(2-(BENZO[D]THIAZOL-2-YL)-2-(PHENYLSUFONAMIDO)ETHYL)BENZIMIDAMIDE DERIVATIVES AND RELATED COMPOUNDS AS TMPRSS2 INHIBITORS FOR THE TREATMENT OF VIRAL INFECTIONS | TMPRSS2, TMPRSS4, TMPRSS11D | TDP1 1943/4885CA12 2790/4885CA1 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.